Kazia advances paxalisib colorectal cancer program

Guggenheim initiated coverage of Kazia Therapeutics with a Buy rating and $35 price target, implying 344.2% upside from the Oct 20 close. The analyst highlights strong clinical data for Paxalisib in treating metastatic triple-negative breast cancer and its unique mechanism of action.

Kazia Therapeutics (KZIA) shares rose 4.1% in pre-market trading after Leerink Partners initiated coverage with an Outperform rating and a $30 price target, citing undervaluation and potential in its cancer drug paxalisib. The stock has a Strong Buy consensus with price targets ranging from $17.51 to $39.25. The rally occurred despite a flat broader market, with upcoming clinical trials serving as catalysts.

Leerink Partners initiated coverage of Kazia Therapeutics with an Outperform rating and $30 price target, implying 282.2% upside from the Oct 19 close. The analyst highlights strong clinical data for Paxalisib in TNBC and GBM, and potential in HR+ breast cancer.

Leerink initiated coverage on Kazia Therapeutics (NASDAQ:KZIA) with an Outperform rating and a $30 price target, implying 282% upside. The company is developing paxalisib for various cancers. Kazia announced a $40M public offering and BTIG raised its target to $40. The stock has a market cap of $107.57M.

Kazia Therapeutics (KZIA) announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders. The milestone triggers a $2 million payment to Kazia, with potential for up to $17 million more. Paxalisib is being developed for intractable epilepsy associated with FCD T2 and TSC, with Kazia retaining oncology focus.

Kazia Therapeutics (KZIA) dosed the first patient in a Phase 2 study of paxalisib combined with gemcitabine for pediatric brain cancer. The trial, conducted by the Pediatric Neuro-Oncology Consortium, follows preclinical data showing increased survival rates. Paxalisib has FDA designations for this indication.